<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
	<id root="FC5C6923-7F62-405F-AD9A-B60901EB5C99"/>
	<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING"/>
	<title mediaType="text/x-hl7-title+xml">CEFOBID&#174;<br/>(sterile cefoperazone, USP)<br/>Formerly known as sterile cefoperazone sodium, USP</title>
	<effectiveTime value="20060407"/>
	<setId root="FC5C6923-7F62-405F-AD9A-B60901EB5C99"/>
	<versionNumber value="1"/>
	<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Roerig</name>
   </representedOrganization>
  </assignedEntity>
</author>
	<component>
		<structuredBody>
			<component>
				<section>
					<id root="69859320-A86E-59FA-0C13-15BC34E4F509"/>
					<effectiveTime value="20060407"/>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0049-1219" codeSystem="2.16.840.1.113883.6.69" codeSystemName="FDA" displayName="NDC"/>
								<name>Cefobid</name>
								<formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
								<activeIngredient>
									<quantity>
										<numerator unit="g" value="10">
											<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="10"/>
										</numerator>
										<denominator value="1">
											<translation code="C48551" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="7U75I1278D" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>cefoperazone</name>
										<activeMoiety>
											<activeMoiety>
												<code code="7U75I1278D" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>cefoperazone</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>cefoperazone</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<quantity>
										<numerator unit="mg" value="340">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="340"/>
										</numerator>
										<denominator value="1">
											<translation code="C48551" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL" value="1"/>
										</denominator>
									</quantity>
									<inactiveIngredientSubstance>
										<name>sodium</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="1">
											<translation code="C48551" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL" value="1"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="0049-1219-28" codeSystem="2.16.840.1.113883.6.69" codeSystemName="FDA" displayName="NDC"/>
										<formCode code="C43212" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, PHARMACY BULK PACKAGE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
				</section>
			</component>
			<component>
				<section>
					<id root="1546B5DD-CCAF-24F5-1602-518B5A102E2A"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml"/>
					<text>
						<paragraph>
							<content styleCode="bold">PHARMACY BULK PACKAGE <br/>NOT FOR DIRECT INFUSION</content>
						</paragraph>
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
			<component>
				<section>
					<id root="517CE058-E49C-6898-952A-D001E89807CA"/>
					<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION"/>
					<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
					<text>
						<paragraph>CEFOBID&#174; (cefoperazone), formerly known as cefoperazone sodium, is a sterile, semisynthetic, broad-spectrum, parenteral cephalosporin antibiotic for intravenous or intramuscular administration. It is the sodium salt of 7-[(<content styleCode="italics">R</content>)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-(<content styleCode="italics">p</content>-hydroxyphenyl)acetamido-3-[[(1-methyl-<content styleCode="italics">H</content>-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. Its chemical formula is C<sub>25</sub>H<sub>26</sub>N<sub>9</sub>NaO<sub>8</sub>S<sub>2</sub> with a molecular weight of 667.65. The structural formula is given below:</paragraph>
						<renderMultiMedia referencedObject="MM1"/>
						<paragraph>CEFOBID contains 34 mg sodium (1.5 mEq) per gram. CEFOBID is a white powder which is freely soluble in water. The pH of a 25% (w/v) freshly reconstituted solution varies between 4.5&#8211;6.5 and the solution ranges from colorless to straw yellow depending on the concentration.</paragraph>
						<paragraph>CEFOBID in crystalline form is supplied in vials equivalent to 1 g or 2 g of cefoperazone.</paragraph>
						<paragraph>A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses.</paragraph>
						<paragraph>This Pharmacy Bulk Package is for use in a pharmacy admixture service; it provides many single doses of cefoperazone for addition to suitable parenteral fluids in the preparation of admixtures for intravenous infusion. (See <linkHtml href="#Dosage_and_Administration">DOSAGE AND ADMINISTRATION</linkHtml>, and <linkHtml href="#Directions_for_Proper_Use_of_Pharmacy">DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE</linkHtml>.)</paragraph>
					</text>
					<effectiveTime value="20060407"/>
					<component>
						<observationMedia ID="MM1">
							<value mediaType="image/jpeg" xsi:type="ED">
								<reference value="cefobid-image01.jpg"/>
							</value>
						</observationMedia>
					</component>
					<component>
						<observationMedia ID="MM2">
							<value mediaType="image/jpeg" xsi:type="ED">
								<reference value="cefobid-image02.jpg"/>
							</value>
						</observationMedia>
					</component>
				</section>
			</component>
			<component>
				<section ID="Clinical_Pharmacology">
					<id root="E820611D-471F-A59B-8330-9C779A16E318"/>
					<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION"/>
					<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
					<text>
						<paragraph>High serum and bile levels of CEFOBID are attained after a single dose of the drug. Table 1 demonstrates the serum concentrations of CEFOBID in normal volunteers following either a single 15-minute constant rate intravenous infusion of 1, 2, 3 or 4 grams of the drug, or a single intramuscular injection of 1 or 2 grams of the drug.</paragraph>
						<table width="65%">
							<caption>TABLE 1. Cefoperazone Serum Concentrations</caption>
							<col align="left" width="15%"/>
							<col align="center" width="12%"/>
							<col align="center" width="15%"/>
							<col align="center" width="10%"/>
							<col align="center" width="10%"/>
							<col align="center" width="10%"/>
							<col align="center" width="10%"/>
							<col align="center" width="10%"/>
							<thead>
								<tr>
									<th/>
									<th/>
									<th colspan="7">Mean Serum Concentrations (mcg/mL)</th>
									<th/>
									<th/>
								</tr>
								<tr>
									<th valign="bottom">Dose/Route</th>
									<th styleCode="Toprule">0<footnote ID="Footnote1">Hours post-administration, with 0 time being the end of the infusion.</footnote>
									</th>
									<th styleCode="Toprule">0.5&#160;hr</th>
									<th styleCode="Toprule">1&#160;hr</th>
									<th styleCode="Toprule">2&#160;hr</th>
									<th styleCode="Toprule">4&#160;hr</th>
									<th styleCode="Toprule">8&#160;hr</th>
									<th styleCode="Toprule">12&#160;hr</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>1 g IV</td>
									<td>153</td>
									<td>114</td>
									<td>73</td>
									<td>38</td>
									<td>16</td>
									<td>4</td>
									<td>0.5</td>
								</tr>
								<tr>
									<td>2 g IV</td>
									<td>252</td>
									<td>153</td>
									<td>114</td>
									<td>70</td>
									<td>32</td>
									<td>8</td>
									<td>2</td>
								</tr>
								<tr>
									<td>3 g IV</td>
									<td>340</td>
									<td>210</td>
									<td>142</td>
									<td>89</td>
									<td>41</td>
									<td>9</td>
									<td>2</td>
								</tr>
								<tr>
									<td>4 g IV</td>
									<td>506</td>
									<td>325</td>
									<td>251</td>
									<td>161</td>
									<td>71</td>
									<td>19</td>
									<td>6</td>
								</tr>
								<tr>
									<td>1 g IM</td>
									<td>32<footnote ID="footnote2">Values obtained 15 minutes post-injection.</footnote>
									</td>
									<td>52</td>
									<td>65</td>
									<td>57</td>
									<td>33</td>
									<td>7</td>
									<td>1</td>
								</tr>
								<tr>
									<td>2 g IM</td>
									<td>40<footnoteRef IDREF="footnote2"/>
									</td>
									<td>69</td>
									<td>93</td>
									<td>97</td>
									<td>58</td>
									<td>14</td>
									<td>4</td>
								</tr>
							</tbody>
						</table>
						<paragraph>The mean serum half-life of CEFOBID is approximately 2.0 hours, independent of the route of administration.</paragraph>
						<paragraph>
							<content styleCode="italics">In vitro</content> studies with human serum indicate that the degree of CEFOBID reversible protein binding varies with the serum concentration from 93% at 25 mcg/mL of CEFOBID to 90% at 250 mcg/mL and 82% at 500 mcg/mL.</paragraph>
						<paragraph>CEFOBID achieves therapeutic concentrations in the following body tissues and fluids:</paragraph>
						<table width="75%">
							<col align="left" width="25%"/>
							<col align="center" width="25%"/>
							<col align="center" width="25%"/>
							<thead>
								<tr>
									<th>Tissue or Fluid</th>
									<th>Dose</th>
									<th>Concentration</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Ascitic Fluid</td>
									<td>2 g</td>
									<td>64 mcg/mL</td>
								</tr>
								<tr>
									<td>Cerebrospinal Fluid (in patients with inflamed meninges)</td>
									<td>50 mg/kg</td>
									<td>1.8 mcg/mL to 8.0 mcg/mL</td>
								</tr>
								<tr>
									<td>Urine</td>
									<td>2 g</td>
									<td>3,286 mcg/mL</td>
								</tr>
								<tr>
									<td>Sputum</td>
									<td>3 g</td>
									<td>6.0 mcg/mL</td>
								</tr>
								<tr>
									<td>Endometrium</td>
									<td>2 g</td>
									<td>74 mcg/g</td>
								</tr>
								<tr>
									<td>Myometrium</td>
									<td>2 g</td>
									<td>54 mcg/g</td>
								</tr>
								<tr>
									<td>Palatine Tonsil</td>
									<td>1 g</td>
									<td>8 mcg/g</td>
								</tr>
								<tr>
									<td>Sinus Mucous Membrane</td>
									<td>1 g</td>
									<td>8 mcg/g</td>
								</tr>
								<tr>
									<td>Umbilical Cord Blood</td>
									<td>1 g</td>
									<td>25 mcg/mL</td>
								</tr>
								<tr>
									<td>Amniotic Fluid</td>
									<td>1 g</td>
									<td>4.8 mcg/mL</td>
								</tr>
								<tr>
									<td>Lung</td>
									<td>1 g</td>
									<td>28 mcg/g</td>
								</tr>
								<tr>
									<td>Bone</td>
									<td>2 g</td>
									<td>40 mcg/g</td>
								</tr>
							</tbody>
						</table>
						<paragraph>CEFOBID is excreted mainly in the bile. Maximum bile concentrations are generally obtained between one and three hours following drug administration and exceed concurrent serum concentrations by up to 100 times. Reported biliary concentrations of CEFOBID range from 66 mcg/mL at 30 minutes to as high as 6000 mcg/mL at 3 hours after an intravenous bolus injection of 2 grams.</paragraph>
						<paragraph>Following a single intramuscular or intravenous dose, the urinary recovery of CEFOBID over a 12-hour period averages 20&#8211;30%. No significant quantity of metabolites has been found in the urine. Urinary concentrations greater than 2200 mcg/mL have been obtained following a 15-minute infusion of a 2 g dose. After an IM injection of 2 g, peak urine concentrations of almost 1000 mcg/mL have been obtained, and therapeutic levels are maintained for 12 hours.</paragraph>
						<paragraph>Repeated administration of CEFOBID at 12-hour intervals does not result in accumulation of the drug in normal subjects. Peak serum concentrations, areas under the curve (AUC's), and serum half-lives in patients with severe renal insufficiency are not significantly different from those in normal volunteers. In patients with hepatic dysfunction, the serum half-life is prolonged and urinary excretion is increased. In patients with combined renal and hepatic insufficiencies, CEFOBID may accumulate in the serum.</paragraph>
						<paragraph>CEFOBID has been used in pediatrics, but the safety and effectiveness in children have not been established. The half-life of CEFOBID in serum is 6&#8211;10 hours in low birth-weight neonates.</paragraph>
					</text>
					<effectiveTime value="20060407"/>
					<component>
						<section>
							<id root="659CDBE2-FF6B-F192-7E64-0CF8B4025854"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Microbiology</title>
							<text>
								<paragraph>CEFOBID is active <content styleCode="italics">in vitro</content> against a wide range of aerobic and anaerobic, gram-positive and gram-negative pathogens. The bactericidal action of CEFOBID results from the inhibition of bacterial cell wall synthesis. CEFOBID has a high degree of stability in the presence of beta-lactamases produced by most gram-negative pathogens. CEFOBID is usually active against organisms which are resistant to other beta-lactam antibiotics because of beta lactamase production. CEFOBID is usually active against the following organisms <content styleCode="italics">in vitro</content> and in clinical infections:</paragraph>
							</text>
							<effectiveTime value="20060407"/>
							<component>
								<section>
									<id root="39D29BB6-D5BF-B46C-41BA-43A76BE9A3D0"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
									<title mediaType="text/x-hl7-title+xml">Gram-Positive Aerobes</title>
									<text>
										<list>
											<item>
												<content styleCode="italics">Staphylococcus aureus</content>, penicillinase and non-penicillinase producing strains</item>
											<item>
												<content styleCode="italics">Staphylococcus epidermidis</content>
											</item>
											<item>
												<content styleCode="italics">
													<content styleCode="italics">Streptococcus pneumoniae</content>
												</content> (formerly <content styleCode="italics">Diplococcus pneumoniae</content>)</item>
											<item>
												<content styleCode="italics">Streptococcus pyogenes</content> (Group A beta-hemolytic streptococci)</item>
											<item>
												<content styleCode="italics">Streptococcus agalactiae</content> (Group B beta-hemolytic streptococci)</item>
											<item>Enterococcus (<content styleCode="italics">Streptococcus faecalis, S. faecium</content> and <content styleCode="italics">S. durans</content>)</item>
										</list>
									</text>
									<effectiveTime value="20060407"/>
								</section>
							</component>
							<component>
								<section>
									<id root="3BBFFC87-990B-6809-8F97-72817FBB49DB"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
									<title mediaType="text/x-hl7-title+xml">Gram-Negative Aerobes</title>
									<text>
										<list>
											<item>
												<content styleCode="italics">Escherichia coli</content>
											</item>
											<item>
												<content styleCode="italics">Klebsiella species</content> (including <content styleCode="italics">K. pneumoniae</content>)</item>
											<item>
												<content styleCode="italics">Enterobacter </content>species</item>
											<item>
												<content styleCode="italics">Citrobacter</content> species</item>
											<item>
												<content styleCode="italics">Haemophilus influenzae</content>
											</item>
											<item>
												<content styleCode="italics">Proteus mirabilis</content>
											</item>
											<item>
												<content styleCode="italics">Proteus vulgaris</content>
											</item>
											<item>
												<content styleCode="italics">Morganella morganii </content>(formerly <content styleCode="italics">Proteus morganii</content>)</item>
											<item>
												<content styleCode="italics">Providencia stuartii</content>
											</item>
											<item>
												<content styleCode="italics">Providencia rettgeri</content> (formerly <content styleCode="italics">Proteus rettgeri</content>)</item>
											<item>
												<content styleCode="italics">Serratia marcescens</content>
											</item>
											<item>
												<content styleCode="italics">Pseudomonas aeruginosa</content>
											</item>
											<item>
												<content styleCode="italics">Pseudomonas</content> species</item>
											<item>Some strains of <content styleCode="italics">Acinetobacter calcoaceticus</content>
											</item>
											<item>
												<content styleCode="italics">Neisseria gonorrhoeae</content>
											</item>
										</list>
									</text>
									<effectiveTime value="20060407"/>
								</section>
							</component>
							<component>
								<section>
									<id root="C54AAD31-54C1-72DA-19F4-54D64FC7FD04"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
									<title mediaType="text/x-hl7-title+xml">Anaerobic Organisms</title>
									<text>
										<list>
											<item>Gram-positive cocci (including <content styleCode="italics">Peptococcus</content> and <content styleCode="italics">Peptostreptococcus</content>)</item>
											<item>
												<content styleCode="italics">Clostridium</content> species</item>
											<item>
												<content styleCode="italics">Bacteroides fragilis</content>
											</item>
											<item>Other <content styleCode="italics">Bacteroides </content>species</item>
										</list>
										<paragraph>CEFOBID is also active <content styleCode="italics">in vitro</content> against a wide variety of other pathogens although the clinical significance is unknown. These organisms include: <content styleCode="italics">Salmonella</content> and <content styleCode="italics">Shigella</content> species,<content styleCode="italics">Serratia liquefaciens, N. meningitidis, Bordetella pertussis, Yersinia enterocolitica, Clostridium difficile, Fusobacterium</content> species, <content styleCode="italics">Eubacterium</content> species and beta-lactamase producing strains of <content styleCode="italics">H. influenzae</content> and <content styleCode="italics">N. gonorrhoeae</content>.</paragraph>
									</text>
									<effectiveTime value="20060407"/>
								</section>
							</component>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="69DE0E26-87C9-A678-EA39-B77FF0501097"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">SUSCEPTIBILITY TESTING</title>
					<text/>
					<effectiveTime value="20060407"/>
					<component>
						<section>
							<id root="295D3C64-8E5D-DB33-221A-56694D626820"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Diffusion Technique</title>
							<text>
								<paragraph>For the disk diffusion method of susceptibility testing, a 75 mcg CEFOBID diffusion disk should be used. Organisms should be tested with the CEFOBID 75 mcg disk since CEFOBID has been shown <content styleCode="italics">in vitro</content> to be active against organisms which are found to be resistant to other beta-lactam antibiotics.</paragraph>
								<paragraph>Tests should be interpreted by the following criteria:</paragraph>
								<table width="40%">
									<col align="left"/>
									<col align="left"/>
									<thead>
										<tr>
											<th>Zone&#160;Diameter</th>
											<th>Interpretation</th>
										</tr>
									</thead>
									<tbody>
										<tr>
											<td>Greater&#160;than&#160;or&#160;equal&#160;to&#160;21&#160;mm</td>
											<td>Susceptible</td>
										</tr>
										<tr>
											<td>16&#8211;20 mm</td>
											<td>Moderately&#160;Susceptible</td>
										</tr>
										<tr>
											<td>Less than or equal to 15 mm</td>
											<td>Resistant</td>
										</tr>
									</tbody>
								</table>
								<paragraph>Quantitative procedures that require measurement of zone diameters give the most precise estimate of susceptibility. One such method which has been recommended for use with the CEFOBID 75 mcg disk is the NCCLS approved standard. (Performance Standards for Antimicrobial Disk Susceptibility Tests. Second Information Supplement Vol. 2 No. 2 pp. 49&#8211;69. Publisher&#8211;National Committee for Clinical Laboratory Standards, Villanova, Pennsylvania.)</paragraph>
								<paragraph>A report of "susceptible" indicates that the infecting organism is likely to respond to CEFOBID therapy and a report of "resistant" indicates that the infecting organism is not likely to respond to therapy. A "moderately susceptible" report suggests that the infecting organism will be susceptible to CEFOBID if a higher than usual dosage is used or if the infection is confined to tissues and fluids (e.g., urine or bile) in which high antibiotic levels are attained.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="6CF27149-6CB9-324F-3E5B-B3E0E70A70C1"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Dilution Techniques</title>
							<text>
								<paragraph>Broth or agar dilution methods may be used to determine the minimal inhibitory concentration (MIC) of CEFOBID. Serial twofold dilutions of CEFOBID should be prepared in either broth or agar. Broth should be inoculated to contain 5 &#215; 10<sup>5</sup> organisms/mL and agar "spotted" with 10<sup>4</sup> organisms.</paragraph>
								<paragraph>MIC test results should be interpreted in light of serum, tissue, and body fluid concentrations of CEFOBID. Organisms inhibited by CEFOBID at 16 mcg/mL or less are considered susceptible, while organisms with MIC's of 17&#8211;63 mcg/mL are moderately susceptible. Organisms inhibited at CEFOBID concentrations of greater than or equal to 64 mcg/mL are considered resistant, although clinical cures have been obtained in some patients infected by such organisms.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="Indications">
					<id root="3E468F74-F1A4-0FBE-041F-223833FCB888"/>
					<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS &amp; USAGE SECTION"/>
					<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
					<text>
						<paragraph>CEFOBID is indicated for the treatment of the following infections when caused by susceptible organisms:</paragraph>
						<paragraph>
							<content styleCode="bold">Respiratory Tract Infections</content> caused by <content styleCode="italics">S. pneumoniae, H. influenzae, S. aureus</content> (penicillinase and non-penicillinase producing strains), <content styleCode="italics">S. pyogenes<footnote ID="FOOTNOTE1">Efficacy of this organism in this organ system was studied in fewer than 10 infections.</footnote>
							</content> (Group A beta-hemolytic streptococci), <content styleCode="italics">P. aeruginosa, Klebsiella pneumoniae, E. coli, Proteus mirabilis</content>, and <content styleCode="italics">Enterobacter</content> species.</paragraph>
						<paragraph>
							<content styleCode="bold">Peritonitis and Other Intra-abdominal Infections</content> caused by <content styleCode="italics">E. coli, P. aeruginosa<footnoteRef IDREF="FOOTNOTE1"/>
							</content> and anaerobic gram-negative bacilli (including <content styleCode="italics">Bacteroides fragilis</content>).</paragraph>
						<paragraph>
							<content styleCode="bold">Bacterial Septicemia</content> caused by <content styleCode="italics">S. pneumoniae, S. agalactiae,<footnoteRef IDREF="FOOTNOTE1"/> S. aureus, Pseudomonas aeruginosa,<footnoteRef IDREF="FOOTNOTE1"/> E. coli, Klebsiella </content>spp.,<footnoteRef IDREF="FOOTNOTE1"/>
							<content styleCode="italics">Klebsiella pneumoniae</content>,<footnoteRef IDREF="FOOTNOTE1"/>
							<content styleCode="italics">Proteus </content>species<footnoteRef IDREF="FOOTNOTE1"/> (indole-positive and indole-negative), <content styleCode="italics">Clostridium</content> spp.<footnoteRef IDREF="FOOTNOTE1"/> and anaerobic gram-positive cocci.<footnoteRef IDREF="FOOTNOTE1"/>
						</paragraph>
						<paragraph>
							<content styleCode="bold">Infections of the Skin and Skin Structures</content> caused by <content styleCode="italics">S. aureus</content> (penicillinase and non-penicillinase producing strains), <content styleCode="italics">S. pyogenes,<footnoteRef IDREF="FOOTNOTE1"/>
							</content> and <content styleCode="italics">P. aeruginosa</content>.</paragraph>
						<paragraph>
							<content styleCode="bold">Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract</content> caused by <content styleCode="italics">N. gonorrhoeae, S. epidermidis,<footnoteRef IDREF="FOOTNOTE1"/> S. agalactiae, E. coli, Clostridium</content> spp.,<footnoteRef IDREF="FOOTNOTE1"/>
							<content styleCode="italics">Bacteroides </content>species (including <content styleCode="italics">Bacteroides fragilis</content>), and anaerobic gram-positive cocci.</paragraph>
						<paragraph>Cefobid, like other cephalosporins, has no activity against <content styleCode="italics">Chlamydia trachomatis</content>. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and <content styleCode="italics">C. trachomatis</content> is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added.</paragraph>
						<paragraph>
							<content styleCode="bold">Urinary Tract Infections</content> caused by <content styleCode="italics">Escherichia coli</content> and <content styleCode="italics">Pseudomonas aeruginosa</content>.</paragraph>
						<paragraph>
							<content styleCode="bold">Enterococcal Infections</content>: Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of <content styleCode="bold">peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections,</content>
							<footnoteRef IDREF="FOOTNOTE1"/> the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, <content styleCode="italics">in vitro</content> susceptibility testing may not correlate directly with <content styleCode="italics">in vivo</content> results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.</paragraph>
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
			<component>
				<section>
					<id root="3FFC9299-F8A8-529F-071F-F90CE613060B"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">Susceptibility Testing</title>
					<text>
						<paragraph>Before instituting treatment with CEFOBID, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Treatment may be started before results of susceptibility testing are available.</paragraph>
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
			<component>
				<section>
					<id root="427982C7-4803-8D49-9251-348DC60B0EBF"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">Combination Therapy</title>
					<text>
						<paragraph>Synergy between CEFOBID and aminoglycosides has been demonstrated with many gram-negative bacilli. However, such enhanced activity of these combinations is not predictable. If such therapy is considered, <content styleCode="italics">in vitro </content>susceptibility tests should be performed to determine the activity of the drugs in combination, and renal function should be monitored carefully. (See <linkHtml href="#Precautions">PRECAUTIONS</linkHtml>, and <linkHtml href="#Dosage_and_Administration">DOSAGE AND ADMINISTRATION </linkHtml>sections.)</paragraph>
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
			<component>
				<section>
					<id root="A310EBE2-469E-B481-05DC-D44239E2A02C"/>
					<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
					<text>
						<paragraph>CEFOBID is contraindicated in patients with known allergy to the cephalosporin-class of antibiotics.</paragraph>
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
			<component>
				<section ID="Warnings">
					<id root="D978EB5E-4C05-3F23-E1CF-7D7CD786C023"/>
					<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
					<text>
						<paragraph>BEFORE THERAPY WITH CEFOBID IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS, PENICILLINS OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE THE USE OF SUBCUTANEOUS EPINEPHRINE AND OTHER EMERGENCY MEASURES.</paragraph>
						<paragraph>PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH THE USE OF CEPHALOSPORINS (AND OTHER BROAD-SPECTRUM ANTIBIOTICS); THEREFORE, IT IS IMPORTANT TO CONSIDER ITS DIAGNOSIS IN PATIENTS WHO DEVELOP DIARRHEA IN ASSOCIATION WITH ANTIBIOTIC USE.</paragraph>
						<paragraph>Treatment with broad-spectrum antibiotics alters normal flora of the colon and may permit overgrowth of clostridia. Studies indicate a toxin produced by<content styleCode="italics"> Clostridium difficile</content> is one primary cause of antibiotic-associated colitis. Cholestyramine and colestipol resins have been shown to bind the toxin <content styleCode="italics">in vitro</content>.</paragraph>
						<paragraph>Mild cases of colitis may respond to drug discontinuance alone.</paragraph>
						<paragraph>Moderate to severe cases should be managed with fluid, electrolyte, and protein supplementation as indicated.</paragraph>
						<paragraph>When the colitis is not relieved by drug discontinuance or when it is severe, oral vancomycin is the treatment of choice for antibiotic-associated pseudomembranous colitis produced by <content styleCode="italics">C. difficile</content>. Other causes of colitis should also be considered.</paragraph>
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
			<component>
				<section ID="Precautions">
					<id root="2B91C92D-0A4B-C540-E3FC-B7AF772C221D"/>
					<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
					<text>
						<paragraph>Although transient elevations of the BUN and serum creatinine have been observed, CEFOBID alone does not appear to cause significant nephrotoxicity. However, concomitant administration of aminoglycosides and other cephalosporins has caused nephrotoxicity.</paragraph>
						<paragraph>CEFOBID is extensively excreted in bile. The serum half-life of CEFOBID is increased 2&#8211;4 fold in patients with hepatic disease and/or biliary obstruction. In general, total daily dosage above 4 g should not be necessary in such patients. If higher dosages are used, serum concentrations should be monitored.</paragraph>
						<paragraph>Because renal excretion is not the main route of elimination of CEFOBID (see <linkHtml href="#Clinical_Pharmacology">CLINICAL PHARMACOLOGY</linkHtml>), patients with renal failure require no adjustment in dosage when usual doses are administered. When high doses of CEFOBID are used, concentrations of drug in the serum should be monitored periodically. If evidence of accumulation exists, dosage should be decreased accordingly.</paragraph>
						<paragraph>The half-life of CEFOBID is reduced slightly during hemodialysis. Thus, dosing should be scheduled to follow a dialysis period. In patients with both hepatic dysfunction and significant renal disease, CEFOBID dosage should not exceed 1&#8211;2 g daily without close monitoring of serum concentrations.</paragraph>
						<paragraph>As with other antibiotics, vitamin K deficiency has occurred rarely in patients treated with CEFOBID. The mechanism is most probably related to the suppression of gut flora which normally synthesize this vitamin. Those at risk include patients with a poor nutritional status, malabsorption states (e.g., cystic fibrosis), alcoholism, and patients on prolonged hyper-alimentation regimens (administered either intravenously or via a naso-gastric tube). </paragraph>
						<paragraph>Prothrombin time should be monitored in these patients and exogenous vitamin K administered as indicated.</paragraph>
						<paragraph>A disulfiram-like reaction characterized by flushing, sweating, headache, and tachycardia has been reported when alcohol (beer, wine) was ingested within 72 hours after CEFOBID administration. Patients should be cautioned about the ingestion of alcoholic beverages following the administration of CEFOBID. A similar reaction has been reported with other cephalosporins.</paragraph>
						<paragraph>Prolonged use of CEFOBID may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.</paragraph>
						<paragraph>CEFOBID should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.</paragraph>
					</text>
					<effectiveTime value="20060407"/>
					<component>
						<section>
							<id root="AF756644-E591-9415-18F8-D77E91E3B2AE"/>
							<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG &amp;OR LABORATORY TEST INTERACTIONS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Drug/Laboratory Test Interactions</title>
							<text>
								<paragraph>A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="8EA6E77A-A43E-CD72-E848-4B80F2A5120D"/>
							<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
							<text>
								<paragraph>Long-term studies in animals have not been performed to evaluate carcinogenic potential. The maximum duration of CEFOBID animal toxicity studies is six months. In none of the <content styleCode="italics">in vivo</content> or <content styleCode="italics">in vitro </content>genetic toxicology studies did CEFOBID show any mutagenic potential at either the chromosomal or subchromosomal level. CEFOBID produced no impairment of fertility and had no effects on general reproductive performance or fetal development when administered subcutaneously at daily doses up to 500 to 1000 mg/kg prior to and during mating, and to pregnant female rats during gestation. These doses are 10 to 20 times the estimated usual single clinical dose. CEFOBID had adverse effects on the testes of prepubertal rats at all doses tested. Subcutaneous administration of 1000 mg/kg per day (approximately 16 times the average adult human dose) resulted in reduced testicular weight, arrested spermatogenesis, reduced germinal cell population and vacuolation of Sertoli cell cytoplasm. The severity of lesions was dose dependent in the 100 to 1000 mg/kg per day range; the low dose caused a minor decrease in spermatocytes. This effect has not been observed in adult rats. Histologically the lesions were reversible at all but the highest dosage levels. However, these studies did not evaluate subsequent development of reproductive function in the rats. The relationship of these findings to humans is unknown.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="154A9E2B-129A-4F11-B704-CEDA916800C1"/>
							<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY"/>
							<title mediaType="text/x-hl7-title+xml">Usage in Pregnancy</title>
							<text>
								<paragraph/>
							</text>
							<effectiveTime value="20060407"/>
							<component>
								<section>
									<id root="2DB0118A-EFE4-ED31-2FE2-1B164D52E19C"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
									<title mediaType="text/x-hl7-title+xml">Pregnancy Category B</title>
									<text>
										<paragraph>Reproduction studies have been performed in mice, rats and monkeys at doses up to 10 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to CEFOBID. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
									</text>
									<effectiveTime value="20060407"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="CFAAEDCC-9950-F1EB-1CB5-A39A944D558B"/>
							<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Usage in Nursing Mothers</title>
							<text>
								<paragraph>Only low concentrations of CEFOBID are excreted in human milk. Although CEFOBID passes poorly into breast milk of nursing mothers, caution should be exercised when CEFOBID is administered to a nursing woman.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="96E54CC6-37EF-8B7C-0104-AC9A07610697"/>
							<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
							<text>
								<paragraph>Safety and effectiveness in children have not been established. For information concerning testicular changes in prepubertal rats, see Carcinogenesis, Mutagenesis, Impairment of Fertility.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="D7235C17-46B5-D49F-6FA4-424B5869D43D"/>
							<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Geriatric Use</title>
							<text>
								<paragraph>Clinical studies of CEFOBID (sterile cefoperazone sodium) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="962AC967-1296-C569-E327-7D6EC769BC48"/>
					<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
					<text>
						<paragraph>In clinical studies the following adverse effects were observed and were considered to be related to CEFOBID therapy or of uncertain etiology:</paragraph>
					</text>
					<effectiveTime value="20060407"/>
					<component>
						<section>
							<id root="DEBD1AD5-1931-DF99-BA0D-3774680AC639"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Hypersensitivity</title>
							<text>
								<paragraph>As with all cephalosporins, hypersensitivity manifested by skin reactions (1 patient in 45), drug fever (1 in 260), or a change in Coombs' test (1 in 60) has been reported. These reactions are more likely to occur in patients with a history of allergies, particularly to penicillin.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="1DFCA18B-68C7-4259-C6F1-60C1445B22B0"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Hematology</title>
							<text>
								<paragraph>As with other beta-lactam antibiotics, reversible neutropenia may occur with prolonged administration. Slight decreases in neutrophil count (1 patient in 50) have been reported. Decreased hemoglobins (1 in 20) or hematocrits (1 in 20) have been reported, which is consistent with published literature on other cephalosporins. Transient eosinophilia has occurred in 1 patient in 10.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="B668A89B-56E8-68E6-17CF-F1B0E89EA998"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Hepatic</title>
							<text>
								<paragraph>Of 1285 patients treated with cefoperazone in clinical trials, one patient with a history of liver disease developed significantly elevated liver function enzymes during CEFOBID therapy. Clinical signs and symptoms of nonspecific hepatitis accompanied these increases. After CEFOBID therapy was discontinued, the patient's enzymes returned to pre-treatment levels and the symptomatology resolved. As with other antibiotics that achieve high bile levels, mild transient elevations of liver function enzymes have been observed in 5&#8211;10% of the patients receiving CEFOBID therapy. The relevance of these findings, which were not accompanied by overt signs or symptoms of hepatic dysfunction, has not been established.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="B48EFB2A-0310-ADE0-2A67-E4DDE686DECD"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Gastrointestinal</title>
							<text>
								<paragraph> Diarrhea or loose stools has been reported in 1 in 30 patients. Most of these experiences have been mild or moderate in severity and self-limiting in nature. In all cases, these symptoms responded to symptomatic therapy or ceased when cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely.</paragraph>
								<paragraph>Symptoms of pseudomembranous colitis can appear during or for several weeks subsequent to antibiotic therapy (see <linkHtml href="#Warnings">WARNINGS</linkHtml>).</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="63110BCD-46BB-8981-0C03-EC8519D41146"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Renal Function Tests</title>
							<text>
								<paragraph>Transient elevations of the BUN (1 in 16) and serum creatinine (1 in 48) have been noted.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="D01A4D5B-4091-4115-358C-E77A8773ADAF"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Local Reactions</title>
							<text>
								<paragraph> CEFOBID is well tolerated following intramuscular administration. Occasionally, transient pain (1 in 140) may follow administration by this route. When CEFOBID is administered by intravenous infusion some patients may develop phlebitis (1 in 120) at the infusion site.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="Dosage_and_Administration">
					<id root="AA66AB93-3FDC-B073-1B9A-5A555AAA3A68"/>
					<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
					<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
					<text>
						<paragraph>
							<content styleCode="bold">Sterile cefoperazone sodium can be administered by IM or IV injection (following dilution). However, the intent of this pharmacy bulk package is for the preparation of solutions for IV infusion only.</content>
						</paragraph>
						<paragraph>The usual adult daily dose of CEFOBID is 2 to 4 grams per day administered in equally divided doses every 12 hours.</paragraph>
						<paragraph>In severe infections or infections caused by less sensitive organisms, the total daily dose and/or frequency may be increased. Patients have been successfully treated with a total daily dosage of 6&#8211;12 grams divided into 2, 3, or 4 administrations ranging from 1.5 to 4 grams per dose.</paragraph>
						<paragraph>When treating infections caused by <content styleCode="italics">Streptococcus pyogenes</content>, therapy should be continued for at least 10 days.</paragraph>
						<paragraph>If <content styleCode="italics">C. trachomatis</content> is a suspected pathogen, appropriate anti-chlamydial coverage should be added, because cefoperazone has no activity against this organism.</paragraph>
						<paragraph>Solutions of CEFOBID and aminoglycoside should not be directly mixed, since there is a physical incompatibility between them. If combination therapy with CEFOBID and an aminoglycoside is contemplated (see <linkHtml href="#Indications">INDICATIONS</linkHtml>) this can be accomplished by sequential intermittent intravenous infusion provided that separate secondary intravenous tubing is used, and that the primary intravenous tubing is adequately irrigated with an approved diluent between doses. It is also suggested that CEFOBID be administered prior to the aminoglycoside. <content styleCode="italics">In vitro</content> testing of the effectiveness of drug combination(s) is recommended.</paragraph>
						<paragraph>In a pharmacokinetic study, a total daily dose of 16 grams was administered to severely immunocompromised patients by constant infusion without complications. Steady-state serum concentrations were approximately 150 mcg/mL in these patients.</paragraph>
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
			<component>
				<section>
					<id root="FA3DF4F0-8AD3-FFBE-6B81-72B90D05C107"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">RECONSTITUTION</title>
					<text>
						<paragraph>The following solutions may be used for the initial reconstitution of CEFOBID sterile powder:</paragraph>
						<table width="75%">
							<caption>Table 1. Solutions for Initial Reconstitution</caption>
							<col align="left" width="40%"/>
							<col align="left" width="35%"/>
							<tbody>
								<tr>
									<td>5% Dextrose&#160;Injection&#160;(USP)</td>
									<td styleCode="Lrule">0.9%&#160;Sodium&#160;Chloride&#160;Injection&#160;(USP)</td>
								</tr>
								<tr>
									<td>5%&#160;Dextrose&#160;and&#160;0.9%&#160;Sodium&#160;Chloride&#160;Injection&#160;(USP)</td>
									<td styleCode="Lrule">Normosol&#174; M and 5% Dextrose </td>
								</tr>
								<tr>
									<td>5% Dextrose and 0.2% Sodium Chloride Injection (USP)</td>
									<td styleCode="Lrule">&#160;&#160;Injection</td>
								</tr>
								<tr>
									<td>10% Dextrose Injection (USP)</td>
									<td styleCode="Lrule">Normosol&#174; R</td>
								</tr>
								<tr>
									<td>Bacteriostatic Water for Injection [Benzyl Alcohol or Parabens] (USP)<footnote ID="FOOTNOTE3">Not to be used as a vehicle for intravenous infusion.</footnote>
										<footnote ID="FOOTNOTE4">Preparations containing Benzyl Alcohol should not be used in neonates.</footnote>
									</td>
									<td styleCode="Lrule">Sterile Water for Injection<footnoteRef IDREF="FOOTNOTE3"/>
									</td>
								</tr>
							</tbody>
						</table>
					</text>
					<effectiveTime value="20060407"/>
					<component>
						<section>
							<id root="CD25D529-9369-B701-9BB8-BAD2B850D6DA"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">General Reconstitution Procedures</title>
							<text>
								<paragraph>CEFOBID sterile powder for intravenous or intramuscular use may be initially reconstituted with any compatible solution mentioned above in Table 1. Solutions should be allowed to stand after reconstitution to allow any foaming to dissipate to permit visual inspection for complete solubilization. Vigorous and prolonged agitation may be necessary to solubilize CEFOBID in higher concentrations (above 333 mg cefoperazone/mL). The maximum solubility of CEFOBID sterile powder is approximately 475 mg cefoperazone/mL of compatible diluent.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
					<component>
						<section>
							<id root="158638E7-E231-8B45-D62E-5E497AB1F624"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Preparation for Intravenous Use</title>
							<text>
								<paragraph/>
							</text>
							<effectiveTime value="20060407"/>
							<component>
								<section>
									<id root="6EFAA447-3231-6D1B-48E1-822C982D5801"/>
									<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
									<title mediaType="text/x-hl7-title+xml">General</title>
									<text>
										<paragraph>CEFOBID concentrations between 2 mg/mL and 50 mg/mL are recommended for intravenous administration.</paragraph>
										<table width="75%">
											<caption>Table 2. Vehicles for Intravenous Infusion</caption>
											<col align="left" width="40%"/>
											<col align="left" width="35%"/>
											<tbody>
												<tr>
													<td>5% Dextrose Injection (USP)</td>
													<td styleCode="Lrule">Lactated&#160;Ringer's&#160;Injection&#160;(USP)</td>
												</tr>
												<tr>
													<td>5% Dextrose and Lactated Ringer's Injection</td>
													<td styleCode="Lrule">0.9% Sodium Chloride Injection (USP)</td>
												</tr>
												<tr>
													<td>5%&#160;Dextrose&#160;and&#160;0.9%&#160;Sodium&#160;Chloride&#160;Injection&#160;(USP)</td>
													<td styleCode="Lrule">Normosol&#174;&#160;M&#160;and&#160;5%&#160;Dextrose&#160;Injection</td>
												</tr>
												<tr>
													<td>5% Dextrose and 0.2% Sodium Chloride Injection (USP)</td>
													<td styleCode="Lrule">Normosol&#174; R</td>
												</tr>
												<tr>
													<td>10% Dextrose Injection (USP)</td>
													<td styleCode="Lrule"/>
												</tr>
											</tbody>
										</table>
									</text>
									<effectiveTime value="20060407"/>
								</section>
							</component>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="Directions_for_Proper_Use_of_Pharmacy">
					<id root="E2E8BB65-B12F-9E84-0AB5-06E167F38714"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE</title>
					<text>
						<paragraph>The 10 gram vial should be reconstituted with 95 mL of sterile water for injection in two separate aliquots in a suitable work area such as a laminar flow hood. Add 45 mL of solution, shake to dissolve and add 50 mL, shake for final solution. The resulting solution will contain 100 mg/mL of cefoperazone. This closure may be penetrated only one time after reconstitution, if needed, using a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents.</paragraph>
						<paragraph>Discard unused solution within 24 hours of initial entry.</paragraph>
						<table width="75%">
							<tbody>
								<tr>
									<td align="center" styleCode="Lrule Rrule">
										<content styleCode="bold">Reconstituted Bulk Solutions Should Not Be Used For Direct Infusion.</content>
									</td>
								</tr>
							</tbody>
						</table>
						<paragraph>Although after reconstitution of the Pharmacy Bulk Package, no significant loss of potency occurs for 24 hours at room temperature and for 5 days if refrigerated, transfer individual dose to appropriate intravenous infusion solutions as soon as possible following reconstitution of the bulk package. Discard unused portions of solution held longer than these recommended periods at room temperature or under refrigeration. The stability of the solution which has been transferred into a container varies according to diluent and concentration. (See <linkHtml href="#Storage_and_Stability">STORAGE AND STABILITY</linkHtml>.)</paragraph>
						<paragraph>The 10 gram vials may be further diluted with the parenteral diluents listed under <content styleCode="bold">Table 2</content>. </paragraph>
					</text>
					<effectiveTime value="20060407"/>
					<component>
						<section>
							<id root="A19AB187-8C4A-BC64-64CE-FB174316CFC1"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Vehicles for Intravenous Infusion</title>
							<text>
								<paragraph>The parenteral diluents and approximate concentrations of CEFOBID that provide stable solutions are presented under STORAGE AND STABILITY.</paragraph>
								<paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section ID="Storage_and_Stability">
					<id root="D9D24415-69FB-E2F0-CAD9-5367E4951A48"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">STORAGE AND STABILITY</title>
					<text>
						<paragraph>CEFOBID sterile powder is to be stored at or below 25&#176;C (77&#176;F) and protected from light prior to reconstitution. After reconstitution, protection from light is not necessary.</paragraph>
						<paragraph>The following parenteral diluents and approximate concentrations of CEFOBID provide stable solutions under the following conditions for the indicated time periods. (After the indicated time periods, unused portions of solutions should be discarded.)</paragraph>
						<table width="75%">
							<col align="left" width="45%"/>
							<col align="right" width="30%"/>
							<thead>
								<tr>
									<th rowspan="2">Controlled&#160;Room&#160;Temperature&#160;(15&#176;&#8211;25&#176;C/59&#176;&#8211;77&#176;F)<br/>24 Hours</th>
									<th valign="bottom">Approximate Concentrations</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Bacteriostatic&#160;Water&#160;for&#160;Injection&#160;[Benzyl&#160;Alcohol&#160;or&#160;Parabens]&#160;(USP)</td>
									<td>300 mg/mL</td>
								</tr>
								<tr>
									<td>5% Dextrose Injection (USP) </td>
									<td>2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>5% Dextrose and Lactated Ringer's Injection </td>
									<td>2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>5% Dextrose and 0.9% Sodium Chloride Injection (USP) </td>
									<td>2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>5% Dextrose and 0.2% Sodium Chloride Injection (USP) </td>
									<td>2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>10% Dextrose Injection (USP) </td>
									<td>2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>Lactated Ringer's Injection (USP) </td>
									<td>2 mg/mL</td>
								</tr>
								<tr>
									<td>0.5% Lidocaine Hydrochloride Injection (USP) </td>
									<td>300 mg/mL</td>
								</tr>
								<tr>
									<td>0.9% Sodium Chloride Injection (USP) </td>
									<td>2 mg to 300 mg/mL</td>
								</tr>
								<tr>
									<td>Normosol&#174; M and 5% Dextrose Injection </td>
									<td>&#160;&#160; 2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>Normosol&#174; R </td>
									<td>&#160;&#160; 2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>Sterile Water for Injection </td>
									<td>100&#160;mg&#160;to&#160;300&#160;mg/mL</td>
								</tr>
							</tbody>
						</table>
						<paragraph>Reconstituted CEFOBID solutions may be stored in glass or plastic syringes, or in glass or flexible plastic parenteral solution containers.</paragraph>
						<table width="75%">
							<col align="left" width="45%"/>
							<col align="right" width="30%"/>
							<thead>
								<tr>
									<th rowspan="2">Refrigerator Temperature (2&#176;&#8211;8&#176;C/36&#176;&#8211;46&#176;F)<br/>5 Days</th>
									<th valign="bottom">Approximate Concentrations</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Bacteriostatic&#160;Water&#160;for&#160;Injection&#160;[Benzyl&#160;Alcohol&#160;or&#160;Parabens]&#160;(USP)</td>
									<td>300 mg/mL</td>
								</tr>
								<tr>
									<td>5% Dextrose Injection (USP) </td>
									<td>2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>5% Dextrose and 0.9% Sodium Chloride Injection (USP) </td>
									<td>2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>5% Dextrose and 0.2% Sodium Chloride Injection (USP) </td>
									<td>2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>Lactated Ringer's Injection (USP) </td>
									<td>2 mg/mL</td>
								</tr>
								<tr>
									<td>0.5% Lidocaine Hydrochloride Injection (USP) </td>
									<td>300 mg/mL</td>
								</tr>
								<tr>
									<td>0.9% Sodium Chloride Injection (USP) </td>
									<td>2 mg to 300 mg/mL</td>
								</tr>
								<tr>
									<td>Normosol&#174; M and 5% Dextrose Injection </td>
									<td>&#160;&#160; 2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>Normosol&#174; R </td>
									<td>&#160;&#160; 2 mg to 50 mg/mL</td>
								</tr>
								<tr>
									<td>Sterile Water for Injection </td>
									<td>100&#160;mg&#160;to&#160;300&#160;mg/mL</td>
								</tr>
							</tbody>
						</table>
						<paragraph>Reconstituted CEFOBID solutions may be stored in glass or plastic syringes, or in glass or flexible plastic parenteral solution containers.</paragraph>
						<table width="75%">
							<col align="left" width="45%"/>
							<col align="right" width="30%"/>
							<thead>
								<tr>
									<th rowspan="2">Freezer Temperature (&#8211;20&#176; to &#8211;10&#176;C/&#8211;4&#176; to 14&#176;F)</th>
									<th valign="bottom">Approximate Concentrations</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>
										<content styleCode="bold">3 Weeks</content>
									</td>
									<td/>
								</tr>
								<tr>
									<td>5% Dextrose Injection (USP) </td>
									<td>50 mg/mL</td>
								</tr>
								<tr>
									<td>5% Dextrose and 0.9% Sodium Chloride Injection (USP)</td>
									<td>2 mg/mL</td>
								</tr>
								<tr>
									<td>5%&#160;Dextrose&#160;and&#160;0.2%&#160;Sodium&#160;Chloride&#160;Injection&#160;(USP)</td>
									<td>2 mg/mL</td>
								</tr>
								<tr>
									<td colspan="2">&#160;&#160;</td>
								</tr>
								<tr>
									<td>
										<content styleCode="bold">5 Weeks</content>
									</td>
									<td/>
								</tr>
								<tr>
									<td>0.9% Sodium Chloride Injection (USP) </td>
									<td>300 mg/mL</td>
								</tr>
								<tr>
									<td>Sterile Water for Injection</td>
									<td>300&#160;mg/mL</td>
								</tr>
							</tbody>
						</table>
						<paragraph>Reconstituted CEFOBID solutions may be stored in plastic syringes, or in flexible plastic parenteral solution containers.</paragraph>
						<paragraph>Frozen samples should be thawed at room temperature before use. After thawing, unused portions should be discarded. Do not refreeze.</paragraph>
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
			<component>
				<section>
					<id root="3023469D-873B-000E-57B2-8EEA0E9BF070"/>
					<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
					<text>
						<paragraph>CEFOBID sterile powder is available in Pharmacy Bulk Package containing cefoperazone sodium equivalent to 10 g cefoperazone &#215; 1 (NDC 0049-1219-28).</paragraph>
					</text>
					<effectiveTime value="20060407"/>
					<component>
						<section>
							<id root="EDDCF377-0C64-DD09-8A04-0336E73D0210"/>
							<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
							<title mediaType="text/x-hl7-title+xml">OTHER SIZE PACKAGES AVAILABLE</title>
							<text>
								<paragraph>CEFOBID sterile powder is available in vials containing cefoperazone sodium equivalent to 1 g cefoperazone &#215; 10 (NDC 0049-1201-83) and 2 g cefoperazone &#215; 10 (NDC 0049-1202-83) for intramuscular and intravenous administration.</paragraph>
							</text>
							<effectiveTime value="20060407"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="C17FFE72-8FD2-6973-AB20-D807FDC3A0F7"/>
					<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="SPL UNCLASSIFIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml"/>
					<text>
						<paragraph>
							<content styleCode="bold">Rx only</content>
						</paragraph>
						<renderMultiMedia referencedObject="MM2"/>
						<paragraph>LAB-0034-3.0</paragraph>
					
					</text>
					<effectiveTime value="20060407"/>
				</section>
			</component>
		</structuredBody>
	</component>
</document>
